Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

Abstract excerpt

Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are sufficient, and whether the addition of germline antigens would enhance the therapeutic efficacy. We developed and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immunotherapy and Immune Responses
• Share to Monoclonal and Polyclonal Antibodies Research
• Share to vaccines and immunoinformatics approaches